Aclaris Therapeutics Inc. (NASDAQ:ACRS) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the stock. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $31.80.
A number of research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. JMP Securities started coverage on shares of Aclaris Therapeutics in a research report on Friday. They issued an “outperform” rating and a $34.00 target price on the stock. Jefferies Group raised their target price on shares of Aclaris Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, September 19th. Finally, Guggenheim started coverage on shares of Aclaris Therapeutics in a research report on Friday, June 10th. They issued a “buy” rating and a $35.00 target price on the stock.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at 25.61 on Friday. Aclaris Therapeutics has a 52-week low of $10.99 and a 52-week high of $33.88. The company’s market cap is $548.44 million. The company has a 50 day moving average of $22.46 and a 200-day moving average of $20.11.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.01. Analysts forecast that Aclaris Therapeutics will post ($2.60) EPS for the current fiscal year.
In other news, major shareholder Ra Capital Management, Llc sold 525,550 shares of Aclaris Therapeutics stock in a transaction on Friday, September 16th. The shares were sold at an average price of $24.19, for a total transaction of $12,713,054.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kamil Ali-Jackson sold 3,738 shares of Aclaris Therapeutics stock in a transaction on Friday, August 26th. The stock was sold at an average price of $20.35, for a total transaction of $76,068.30. Following the transaction, the insider now owns 20,289 shares in the company, valued at approximately $412,881.15. The disclosure for this sale can be found here. 46.40% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. raised its position in shares of Aclaris Therapeutics by 40.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 23,715 shares of the company’s stock worth $439,000 after buying an additional 6,852 shares during the period. Sabby Management LLC acquired a new position in shares of Aclaris Therapeutics during the second quarter worth approximately $292,000. Opaleye Management Inc. raised its position in shares of Aclaris Therapeutics by 122.2% in the second quarter. Opaleye Management Inc. now owns 40,000 shares of the company’s stock worth $326,000 after buying an additional 22,000 shares during the period. State Street Corp raised its position in shares of Aclaris Therapeutics by 64.8% in the second quarter. State Street Corp now owns 120,010 shares of the company’s stock worth $2,217,000 after buying an additional 47,179 shares during the period. Finally, Teachers Advisors Inc. raised its position in shares of Aclaris Therapeutics by 91.0% in the second quarter. Teachers Advisors Inc. now owns 14,212 shares of the company’s stock worth $262,000 after buying an additional 6,772 shares during the period. Institutional investors own 71.39% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.